Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Liquid Biopsy Unlocking essential genomic information from a simple blood draw to transform the care of cancer patients

InVision® platform

Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients

InVisionFirst®Lung Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients

InVisionFirst®Lung

Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients

Radar™  A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform

Radar

A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform

Our Mission

We are transforming the lives of cancer patients and their families through the power of liquid biopsy

InvisionFirst Lung - ctDNA Liquid Biopsy Test

Our Technology - Liquid Biopsy Testing

Our Technology

Contact Us at Inivata

Contact Us

Latest News and Events

Inivata Announces RaDaR™ Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program

Inivata, a leader in liquid biopsy, today announced that it has received the CE mark for its RaDaR™ assay for the detection of molecular residual disease (MRD) and recurrence, having met the requirements of the European In-Vitro Diagnostics Directive (98/79/EC). In addition, Inivata has submitted to the MolDX program in the US for the reimbursement of RaDaR for clinical testing. Read More

Liquid biopsies for residual disease and recurrence

Jonathan Chee Ming Wan, Tariq Imdadali Mughal, Pedram Razavi, Sarah-Jane Dawson, Esther Louise Moss, Ramaswamy Govindan, Iain Beehuat ... Read More

LBx 2022

LBx 2022

Event expiration date display - 10 - 11 FEB 2022

Location: San Diego, CA Read More

Changing Lives

Patients are at the heart of everything we do.

Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients’ lives. 

This is the story of the first patient Inivata tested.

Transforming the lives of Cancer Patients and Their Families

As a dynamic and innovative company, we focus on the development of ground-breaking technology in a fast-paced and international setting.

Our team of talented and driven individuals work together to combine their energy and expertise in world-class research, product development and commercialization. Join us.

We have a new white paper on RaDaR™, a highly sensitive & specific #ctDNA assay for the detection of molecular residual & recurrent disease (#MRD). To find out more about the #assay request a copy of the white paper here: https://www.inivata.com/about-us/contact-us/

We are proud to be partnering with the LBX #LiquidBiopsy Precision Oncology Summit in February. Join #TeamInivata & others in addressing the key challenges in progressing precision oncology pipelines by harnessing liquid biopsy technology.
Learn more here: https://lbx-summit.com/

Read our latest Med review titled ‘Liquid biopsies for residual disease and recurrence’ published in @CellCellPress

LinkedIn tracking code Twitter tracking code